Stefania Bellone, PhD
Research & Publications
Biography
News
Extensive Research Description
Dr. Stefania Bellone's research has been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals. Dr. Bellone’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. She is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma. Her research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies. Dr. Bellone has initiated and completed multiple investigator’s initiated FDA approved clinical trials in gynecologic patients using novel immunotherapeutic strategies developed and characterized in Dr. Alessandro Santin's laboratory.
Coauthors
Selected Publications
- Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. American Journal Of Obstetrics And Gynecology 2009, 200:75.e1-10.
- Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. Journal Of Virology 2008, 82:1968-79.
- Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Cancer 2009, 115:800-11.
- Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. Journal Of Virology 2009, 83:6779-89.
- Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2009, 19:860-6.
- Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101:335-41.